pathobiology, being involved in the development of coronary restenosis and atherosclerosis. The activation of nuclear proto-oncogenes appears to be a final common pathway onto which various mitogenic signals converge. Accordingly, we attempted to determine whether the activation of the c-myc nuclear proto-oncogene is essential for human SMC proliferation and explored the possibility of inhibiting their growth using antisense oligonucleotides directed against c-myc messenger RNA (mRNA). Methods and Results. Proliferation of human SMCs was associated with an increase in c-myc mRNA expression after growth stimulation. Using 15-mer phosphorothioate oligonucleotides (oligomers), we tested their growth-inhibitory effect in SMCs in vitro. Antisense oligomers directed against the translation initiation region of the human c-myc gene exhibited a significant antiproliferative effect, whereas sense and mismatched oligomers did not inhibit the growth. The growth-inhibitory effect of c-myc antisense oligomers was dose dependent and preventable by an excess of sense oligomers. Furthermore, growth inhibition of SMCs treated with c-myc antisense oligomers was associated with a marked decrease in the c-myc mRNA level. Phosphorothioate oligomers remained stable in medium containing 20f% serum and were detectable in SMCs as early as 1 hour after cell exposure. Intact oligomers rapidly accumulated intracellularly and persisted within human SMCs for at least 16 hours.
Conclusions. c-myc antisense oligomers reduced c-myc expression and produced a significant growth inhibition of human SMCs, indicating an important role of c-myc gene activation in the process of SMC proliferation. Furthermore, extracellular stability and rapid cellular uptake provide the basis for future studies assessing the therapeutic role of the c-myc antisense approach in reducing SMC proliferation in the process of vascular restenosis. (Circulation. 1993;88:1190-1195.) KEY 
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Nuclear proto-oncogenes are highly conserved phosphoproteins tightly linked to cellular proliferation. The transient increase in nuclear proto-oncogene messenger RNA (mRNA) after mitogenic stimulation has been shown as the cell enters the G1 phase and appears to be necessary for the G1-to-S-phase transition.9,10 Studies in cultured SMCs have demonstrated that c-fos, c-myc, and c-myb proto-oncogenes are activated shortly after various mitogenic stimuli.11,12 Proto-oncogene expression has also been induced in the vessel wall after balloon denudation in a pattern similar to in vitro studies. (Fig 1) .
Inhibition of SMC Proliferation and c-myc Expression
The incubation of human SMCs with c-myc antisense phosphorothioate oligomers resulted in a significant growth-inhibitory effect, whereas sense or mismatched phosphorothioate oligomers exerted no effect on cell growth (Fig 2) . A significant inhibition was maintained for at least 4 days with a continuous exposure to oligomers (P< .001). In contrast to the growth-inhibitory effect of phosphorothioate oligomers, unmodified antisense oligomers had no effect on SMC growth in doses up to 40 t.tmolIL. As expected, the antiproliferative effect of c-myc antisense phosphorothioate oligomers was dose-dependent within a range of 1 to 10 limol/L (Fig 3) withdrawn after 8 hours of incubation, and human SMCs were subcultured 7 days later. The cell counts were obtained at 1, 2, 4, and 6 days thereafter. The growth rates of antisense-treated and control SMCs were identical. This demonstrates normal SMC viability after antisense oligomer treatment.
We expected that the antiproliferative effect of c-myc antisense oligomers would be abrogated by the addition of excess sense oligomers to the SMC culture. As shown in Fig 4, 
Discussion
The major findings of this study are that (1) proliferation of human SMCs is associated with increased expression of the c-myc nuclear proto-oncogene, (2) c-myc antisense phosphorothioate oligomers decrease c-myc expression and produce a significant growthinhibitory effect in human SMCs, and (3) the rapid cellular uptake and relative stability of phosphorothioate oligomers suggest potential applicability of the antisense approach as a therapeutic modality in the cardiovascular system.
Nuclear Proto-oncogene c-myc in SMC Proliferation
The c-myc proto-oncogene, one of the first described nuclear proto-oncogenes, is an evolutionarily conserved gene expressed in numerous cell types. It has been postulated that c-myc has a role as a direct transcriptional activators stimulates DNA replication,21 or regulates gene expression at the posttranscriptional level.22 C-myc protein demonstrates extensive homology with known transcriptional regulators. In addition, helix-loop-helix and leucine zipper domains in c-myc protein are functionally relevant for protein-protein interaction. 3 The results of this study have demonstrated that the c-myc transcripts were elevated in proliferating but not quiescent human SMCs. The c-myc transcripts increased early after cell stimulation and then declined, although their level remained elevated at 24 hours after stimulation. These findings are consistent with observations that c-myc mRNA and protein levels are highest before DNA synthesis (S phase) and then remain above the basal level throughout the cell cycle in the presence of growth factors. ' to provide a new therapeutic modality. The advantages of this approach may include selective inhibition of proliferating cells, suppression of specific gene products in target SMCs, and bypassing of cell surface events such as the activation of membrane receptors. However, a slow cellular uptake and the instability of oligomers in a biological environments raised questions about their applicability in the cardiovascular system, since antisense oligomers must reach sufficient intracellular concentration to exert a therapeutic effect. Phosphorothioate oligomers used in this study remained relatively stable in serum, with about 50% oligomers intact after 36 hours of incubation. These findings are consistent with previous reports indicating that phosphorothioate (ie, sulfur-protected) oligomers are more resistant to enzymatic degradation by deoxyribonucleases present both in serum and within the cells.29 In contrast, even higher concentrations of unmodified c-myc antisense oligomers have failed to inhibit human SMC growth, probably as a result of their instability. It has been suggested that oligonucleotides are actively transported across cell membranes via receptor-mediated endocytosis.17 Since cellular uptake may differ considerably between different cell lines, it was important to determine oligonucleotide transport into human SMCs. The results of this study demonstrate rapid accumulation of intact oligomers within human SMCs starting as early as 1 hour after exposure. A significant amount of intact oligomers persisted within human SMCs for at least 16 hours. Hence, the presence of intact oligonucleotides in the extracellular environment allowed maintenance of their sustained intracellular concentration. Recently, Simons and Rosenberg30 have shown the growth-inhibitory effect of c-myb antisense oligomers in rat SMCs. Our own observations indicate that c-myb antisense oligomers (10 umol/L) inhibit human SMC growth as well, with antiproliferative activity comparable to that of c-myc antisense oligomers (unpublished data). Thus, inhibition of different nuclear proto-oncogenes appears to be effective, confirming their essential role in signal transduction in human SMCs. In contrast to a low dose requirement for c-myc and c-myb antisense oligomers (10 Mmol/L) in human SMCs, the growth inhibition of rat SMCs has been previously shown with only high concentrations of phosphoroamidate antisense oligonucleotides complementary to proliferating cell nuclear antigen31 and c-myc mRNA. 32 These data suggest that the type of oligomers used, species differ-ences, and selection of the target mRNA play an important role in biological response to antisense molecules. Further studies are necessary to evaluate the c-myc antisense approach in vivo. Several issues should be taken into consideration, including the mode of local delivery of oligomers to the site of vascular injury and the selection of relevant animal models. Recently, Simons et a133 reported encouraging results regarding adventitial delivery of c-myb antisense oligomers, which reduced formation of neointima after balloon injury in rat carotid arteries. However, the efficacy of the antisense approach with more practical (eg, endoluminal) means of oligomer delivery remains to be evaluated.
Conclusions
In conclusion, c-myc antisense oligomers reduced c-myc expression, which was associated with a significant growth inhibition of human SMCs. This demonstrates that c-myc gene activation plays an important role in the process of human SMC proliferation. A potent growth-inhibitory effect and pharmacokinetic profile of c-myc antisense oligomers provide the basis for studies assessing the therapeutic role of this approach in vascular restenosis.
Note added in proof Since the submission of this manuscript, we have observed a significant inhibition of vascular SMC proliferation in vivo. Proto-oncogene c-myc antisense oligomers delivered locally via a porous balloon reduced neointima formation in denuded porcine coronary arteries.
